Novartis sells Colorado site to maker of CBD products

A Colorado company will make CBD products at this Sandoz site near Boulder that it bought from Novartis for $18.75 million. It is not Novartis' first brush with the marijuana industry. (Mile High Labs)

A manufacturing facility that Novartis discarded because of declining generics sales is getting a new life. The plant near Boulder, Colorado, will be converted to produce CBD products from hemp by a company riding that wave.

Mile High Labs says it closed the deal last week, paying Novartis $18.75 million for the 400,000-square-foot Sandoz production facility in Broomfield, Colorado, which it intends to use to make private-label CBD products. 

“This transaction is the largest infrastructure purchase in the history of the CBD market and it’s only the beginning for Mile High Labs,” Stephen Mueller, chief technology officer and founder of Mile High Labs, said in a statement. “Over the coming quarters, we plan to leverage this tremendous infrastructure to build the global center for CBD products manufacturing.”

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

RELATED: Generics squeeze forces Novartis Colorado plant to close, imperiling 450 jobs

CBD is cannabidiol, an extract from hemp—a cousin of marijuana—and is commonly used as a home treatment for a wide variety of conditions. .

Novartis declined to comment, but Mile High spokesman Christopher Lackner said the transaction closed June 19 and includes the land, labs, buildings and all of the drug manufacturing equipment.

He said the company expects to have the facility operational within months and have 100 employees there by the end of the year. It intends to make products at the plant that include tinctures, capsules, tablets, topicals and gummies.  

Mile High also hopes to hire some of the 450 former employees of the plant. “There is a lot of great knowledge about the operation of that plant and about quality,” Lackner said. “We hope to draw on that.” 

RELATED: Novartis blazes Big Pharma trail, striking deal with Canadian company to distribute medical marijuana products

The Swiss drugmaker signaled its plans to close the Sandoz plant in 2017 after generics prices crashed in the U.S. and the company decided to remake its generics business to focus on higher-margin, complex copies. Meanwhile, the branded company is moving to take the lead in the gene therapy field, which requires an entirely different kind of production.

Novartis closed or sold eight facilities last year and is restructuring eight others to be more efficient, moves that led to nearly 2,000 job cuts. More cuts are expected over the next 18 months as Novartis transforms Sandoz into an “autonomous unit within Novartis.” 

Novartis and Sandoz already have some experience with the medical marijuana industry, having struck a deal last year to distribute products for a Canadian company that sells medical cannabis products in its home country and in Europe.

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.